PPARGC1A and metabolic dysfunction-associated steatotic liver disease: NAFLD is often accompanied by obesity, hypertriglyceridemia, type 2 diabetes, and insulin resistance [30], and PPARGC1A knockout mice develop hepatic steatosis [12].